Erythropoietin biosimilar - Pooyesh Darou

Drug Profile

Erythropoietin biosimilar - Pooyesh Darou

Latest Information Update: 20 Sep 2016

Price : $50

At a glance

  • Originator Pooyesh Darou
  • Class Antianaemics; Erythropoietins
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 23 Jul 2015 Pooyesh Darou completes enrolment in its phase I/II trial for Solid tumours in Iran (IRCT2015061822805N1)
  • 21 Apr 2014 Phase-I/II clinical trials in Solid tumours in Iran (SC) (IRCT2015061822805N1)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top